The Washington Post reviews the extraordinary effort to save Donald Trump from COVID-19, in an excerpt from Nightmare Scenario: Inside the Trump Administration’s Response to the Pandemic That Changed History.
“A five-day stretch in October 2020 — from the moment White House officials began an extraordinary effort to get Trump lifesaving drugs to the day the president returned to the White House from the hospital — marked a dramatic turning point in the nation’s flailing coronavirus response. Trump’s brush with severe illness and the prospect of death caught the White House so unprepared that they had not even briefed Vice President Mike Pence’s team on a plan to swear him in if Trump became incapacitated…”
“The doctors gave Trump an eight-gram dose of two monoclonal antibodies through an intravenous tube. That experimental treatment was what had required the FDA’s sign-off. He was also given a first dose of the antiviral drug remdesivir, also by IV. That drug was authorized for use but still hard to get for many patients because it was in short supply.”
“Typically, doctors space out treatments to measure a patient’s response. Some drugs, such as monoclonal antibodies, are most effective if they’re administered early in the course of an infection. Others, such as remdesivir, are most effective when they’re given later, after a patient has become critically ill. But Trump’s doctors threw everything they could at the virus all at once. His condition appeared to stabilize somewhat as the day wore on, but his doctors, still fearing he might need to go on a ventilator, decided to move him to the hospital. It was too risky at that point to stay at the White House.”
Save to Favorites